The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2018Searching for and Targeting Calcium Channels that Control Alpha-synuclein Release
Study Rationale:
Being the primary component of Lewy bodies -- protein clumps that are the pathological hallmark of Parkinson's disease (PD) -- the protein alpha-synuclein plays the central role in PD... -
Research Grant, 2018PAK6 Activity as a Therapeutic Target in LRRK2-associated Parkinson's Disease
Study Rationale:
Mutations (changes) in the gene for the leucine-rich repeat kinase 2 (LRRK2) protein cause inherited Parkinson's disease (PD). Because the activity of LRRK2 is increased in such mutant... -
Research Grant, 2018Studying Monocyte Entry into the Brain in Alpha-synuclein-induced Parkinson's Disease (supplement)
Study Rationale:
In the past, we demonstrated that entry of CCR2-positive monocytes into the brain is required for alpha-synuclein-induced inflammation and neurodegeneration in a model of Parkinson's... -
Research Grant, 2018Measuring Protein Modifications to Monitor the Efficacy of LRRK2 Inhibitors
Study Rationale:
Leucine-rich repeat kinase 2 (LRRK2) is the greatest known genetic contributor to Parkinson's disease (PD). One important function of LRRK2 is to modify itself and proteins called Rab... -
Target Advancement Program, 2018Interactions Between Alpha-synuclein and Glycoproteins as a Therapeutic Target
Study Rationale:
In Parkinson's disease (PD), the sticky protein alpha-synuclein clumps in the brain, causing cell death. Such toxic alpha-synuclein clumps can spread from cell to cell and multiply. It... -
Target Advancement Program, 2018Investigating Alpha-synuclein Clumping in the Organoid Model of Parkinson's Disease
Study Rationale:
Alpha-synuclein -- a sticky protein that clumps in the brains of people with Parkinson's disease (PD) -- is a major target for the development of therapies for PD. Alpha-synuclein...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.